Cargando…
NTRK-1 fusion in endocervical fibroblastic malignant peripheral nerve sheath tumor marking eligibility for larotrectinib therapy: A case report
• <1% of cervical cancers are sarcomas. • Data on neurofibrosarcoma management is scarce. • Larotrectinib is approved for NTRK1 gene fusion tumors without acquired resistance. • Targeted therapy of tumor genes may expand treatment for a rare cervical sarcoma.
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506462/ https://www.ncbi.nlm.nih.gov/pubmed/31080864 http://dx.doi.org/10.1016/j.gore.2019.04.006 |